Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
By Florence Guivel-benhassine, Aurelie Velay & Isabelle Staropoli
Study shows booster shot after 6 to 12 months likely to provide best protection from COVID-19, Pfizer says
By Mark Osborne & Eric M. Strauss
There is no evidence that the Delta variant of SARS-CoV-2 has a lower fatality rate than the wild-type virus
By Ruben Portela Carballeira
With an uptick in Covid-19 cases, there is growing alarm. 'We've seen almost an entire takeover in the Delta variant,' one state official says
By Aya Elamroussi
Pfizer's COVID-19 booster shot strongly extends protection but CDC cautions 3rd dose not yet needed
By Karen Weintraub